The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Last two holdings rns they have faith .Gla
So, CFO of over US$5 billion company takes 9% stake in N4P. Think that's right. WHY?????
MATHENZ MARC KAY . . . . Pine Labs . . . . . an Indian company that provides financing and retail transaction technology. Founded in 1998, it is a unicorn startup, with a valuation of over US$5 billion.
What does Luke do anyway? Is with N4 and draws a wage, but for what though?
Wowsers, nice to see someones taken a big 9% chunk here.
Results due any time now....
Lots of potential catalysts due this year with the Nanogenics work so hopefully the N4 management will finally be able to add some positive momentum to the share price.
He may be the right man for the job as the The 5 year chart of VAL looks almost identical to N4P's, i.e terrible...
Luke Cairns, Executive Director of N4p, now also a Non Exec at VAL.
Interesting my trade is not published yet, but a small sell is . I decided if I think of investing here as scrapping an old banger it doesn’t seem quite as bad as cash amounts so from now on think of buying shares here as scrapping an old banger. Where there’s muck there’s brass, or tin
Hard to work out the cash position. 1.2million in june. Spent 250k on nanogenics. Raised 1 million. Looks like the cash is the market cap give or take a couple of Puntos. So have added another small Punto before the men in white coats take me away
I feel ( Hope)The risk -reward is changing here and bravery may be hugely rewarded
It hasn't seemed to have any impact. It's a baron tradeless desert out there today
He's the American guy.
Freire has been invested a long time , so I guess he has got his average down a bit. I googled him but not much. There is a Guy in NZ and one in Linked in. Don’t know if he has a medical or scientific background. Also a David Farrier in America in Audio business. Rather he had saved his money to put directly into N4p than buying shares. Maybe they won’t need it after all. Going to be a long year though, assuming they survive!
That's a fantastic article.
let's hope the space see's many more of these.
Thank you for sharing
Some say, he’s the Chuck Norris of AIM.. no fear
The game is afoot finally
Holdings increased above 6% - do we know who he is
“Non-viral, non-lipid delivery systems are in high demand in the exciting gene therapy and oncology spaces and we now have two such delivery systems,” Nigel Theobald, CEO of N4 Pharma, said in the company’s news release. “Nuvec continues to show its versatility as a novel delivery system and with LipTide we are developing our first commercial product which we are aiming to take into phase 1 clinical trials.”
'The company will now engage in discussions with the FDA and MHRA to approve a GLP toxicity study and first in human clinical trials.'
Written by Nigel and David Templeton. This has been the stated aim since the vaccination delivery system was not taken up. I really wonder why they don’t have specific drug manufacturers to target. Just plugging retail investors is not going to get a contract
We are delighted to share the release of our latest scientific paper outlining a drug delivery strategy poised to redefine cancer therapy.
Here's an overview of what we've uncovered:
Addressing treatment challenges: Current approaches to cancer treatment are limited by high general toxicity and low efficacy, driving a pressing need for novel, innovative treatment strategies.
Unlocking potential with combination therapy: Drawing inspiration from successful combination treatments in other medical fields, combination approaches could hold tremendous promise in enhancing treatment efficacy and overcoming resistance mechanisms.
Focusing on siRNA delivery: With small interfering RNA (siRNA) becoming increasingly used in the development of therapeutics, it is critical that these nucleic acids are delivered to tumours safely and efficiently. Dual delivery of siRNA, with or without a relevant, additional, small-molecule therapeutic agent, may be the key to unlocking a new era of treatment efficiency in cancer.
Innovative delivery platform: Departing from conventional delivery methods, mesoporous silica nanoparticles (MSNs) offer a potential solution for precise drug delivery. A novel silica nanoparticle delivery system has been developed (Nuvec®, N4 Pharma) specifically to safely and efficiently deliver siRNAs to tumours to inhibit multiple tumour growth factor pathway. Novel delivery systems that allow for double or even multiple siRNA loading will be critical to the success of future siRNA-based cancer therapeutics.
We believe this drug delivery approach provides a clear strategy to pave the way for more targeted and efficient first-line cancer therapy. A solid delivery platform will be pivotal in allowing developers to realise their goals.
2 x £1 buys
And a 50p sell !!!
We're up 3 % 🤣🤣
Any chance I can get me thousands back Nigel
It's hard to dispute that Vander. I think all of us LTH have some faith in the product or we wouldn't be here but i must admit my medical science knowledge is pretty much zero.
still hoping we haven't backed a donkey but i have only seen things get worse over the 5 years i have been invested.
fingers are still firmly crossed.
This is not gaining momentum or generating much excitement in the scientific community
To do so requires some academic endorsement through journal publications or conference presentations
Its stuck near the start line